REG - Futura Medical PLC - Nominated Adviser and Joint Broker

Futura MedicalAnnouncement

01/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240701:nRSA4821Ua&default-theme=true

RNS Number : 4821U  Futura Medical PLC  01 July 2024

 Futura Medical plc

("Futura", "the Group" or the "Company")

Nominated Adviser and Joint Broker

 

Futura Medical plc (AIM: FUM), the consumer healthcare company behind
Eroxon®, that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, announces that,
following the completion of the all-share merger between Liberum Capital
Limited and Panmure Gordon Group Limited, the Company's Nominated Adviser and
Joint Broker is Panmure Liberum Limited.

 

 

Contacts:

 Futura Medical plc              James Barder               investor.relations@futuramedical.com

                          (mailto:Investor.relations@futuramedical.com)
                                 Chief Executive Officer

                          +44 (0)1483 685 670
                                 Angela Hildreth

                          www.futuramedical.com (http://www.futuramedical.com/)
                                 Finance Director and COO

 Panmure Liberum                 Richard Lindley            +44 (0)20 3100 2000

 Nominated Adviser               Nikhil Varghese

 and Broker

 Stifel Nicolaus Europe Limited  Alan Selby                 +44 (0)207 710 7600

 Joint Broker                    Ben Maddison

 Alma Strategic Communications   Rebecca Sanders-Hewett     +44 (0)20 3405 0205

                                 Sam Modlin                 futura@almastrategic.com

                                 Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon. Our core strength lies in our
research, development and commercialisation of topically delivered gel
formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs
in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe. Eroxon has been nominated for a number
of healthcare industry awards and has won two to-date.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKKBNKBKBOAN